title: Ð¥Ð°ÑÐ°ÐºÑÐµÑÐ¸Ð·Ð°ÑÐ¸Ñ Ð°Ð½ÑÐ¸ÑÐµÐ» Ð¿ÑÐ¾ÑÐ¸Ð² Ð½ÐµÐºÐ¾ÑÐ¾ÑÑÑ ÐºÐ¾Ð¼Ð¿Ð¾Ð½ÐµÐ½ÑÐ¾Ð² Ð¾Ð¿ÑÑ Ð¾Ð»ÐµÐ²Ð¾Ð¹ ÑÑÑÐ¾Ð¼Ñ
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¼Ð°Ð³Ð¸ÑÑÑÐ°
titleType: Subtitle
title: Characterisation of antibodies against some components of tumour stroma
Creators: name: ÐÐ¾ÑÑÑÑÐµÐ²Ð°, ÐÐ»Ð¸Ð½Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2024
Subjects: Ð¿ÑÐ¾ÑÐ¸Ð²Ð¾Ð¾Ð¿ÑÑ Ð¾Ð»ÐµÐ²Ð°Ñ ÑÐµÑÐ°Ð¿Ð¸Ñ
Ð¼Ð¾Ð½Ð¾ÐºÐ»Ð¾Ð½Ð°Ð»ÑÐ½Ð¾Ðµ Ð°Ð½ÑÐ¸ÑÐµÐ»Ð°
anti-tumor therapy
monoclonal antibodies

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° ÑÐ°ÑÐ°ÐºÑÐµÑÐ¸Ð·Ð°ÑÐ¸Ð¸ Ð¼Ð¾Ð½Ð¾ÐºÐ»Ð¾Ð½Ð°Ð»ÑÐ½ÑÑ (Ð¼ÐÐ¢) Ð¸ ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½ÑÑ (ÐºÐ¾Ð½ÑÑÐ¾Ð»ÑÐ½ÑÑ) Ð°Ð½ÑÐ¸ÑÐµÐ» (ÐºÐÐ¢) Ðº ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ°Ð¼ VEGFR-1, CTLA-4 Ð¸ Stabilin-1, Ð¿ÑÐµÐ´ÑÑÐ°Ð²Ð»ÐµÐ½Ð½ÑÐ¼ Ð½Ð° ÐºÐ»ÐµÑÐºÐ°Ñ Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²Ð¾Ð¹ ÑÑÑÐ¾Ð¼Ñ Ð¸ Ð¿Ð¾Ð»ÑÑÐµÐ½Ð¸Ñ ÐºÐ»ÐµÑÐ¾ÑÐ½Ð¾Ð¹ Ð»Ð¸Ð½Ð¸Ð¸, Ð¿ÑÐ¾Ð´ÑÑÐ¸ÑÑÑÑÐµÐ¹ Ð±Ð¸ÑÐ¿ÐµÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¾Ðµ Ð°Ð½ÑÐ¸ÑÐµÐ»Ð¾ (Ð±Ð¸ÐÐ¢). ÐÑÑÐ¸Ð½Ð½Ð¾ÑÑÑ Ð°Ð½ÑÐ¸ÑÐµÐ» Ð¿ÑÐ¾Ð²ÐµÑÑÐ»Ð¸ Ð¼ÐµÑÐ¾Ð´Ð¾Ð¼ ÐÐ¤Ð, ÑÐ¿Ð¾ÑÐ¾Ð±Ð½Ð¾ÑÑÑ ÑÐ²ÑÐ·ÑÐ²Ð°ÑÑÑÑ Ñ Ð½Ð°ÑÐ¸Ð²Ð½ÑÐ¼ Ð°Ð½ÑÐ¸Ð³ÐµÐ½Ð¾Ð¼ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ Ð¿ÑÐ¾ÑÐ¾ÑÐ½Ð¾Ð¹ ÑÐ¸ÑÐ¾Ð¼ÐµÑÑÐ¸Ð¸. ÐÑÐ¾Ð»Ð¸ÑÐµÑÐ°ÑÐ¸Ð²Ð½ÑÑ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÑ ÐºÐ»ÐµÑÐ¾Ðº Ð² Ð¿ÑÐ¸ÑÑÑÑÑÐ²Ð¸Ð¸ Ð°Ð½ÑÐ¸ÑÐµÐ» Ð¾ÑÐµÐ½Ð¸Ð²Ð°Ð»Ð¸ Ð½Ð° ÑÐ¸ÑÑÐµÐ¼Ðµ xCellLigence. Ð ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ Ð±ÑÐ»Ð¾ Ð¿Ð¾ÐºÐ°Ð·Ð°Ð½Ð¾, ÑÑÐ¾ Ð²ÑÐµ Ð¸ÑÑÐ»ÐµÐ´ÑÐµÐ¼ÑÐµ Ð¼ÐÐ¢ Ð¸ ÐºÐÐ¢ Ðº ÑÐµÑÐµÐ¿ÑÐ¾ÑÑ VEGFR-1 Ð¾Ð±Ð»Ð°Ð´Ð°ÑÑ Ð²ÑÑÐ¾ÐºÐ¾Ð¹ Ð°ÑÑÐ¸Ð½Ð½Ð¾ÑÑÑÑ Ðº ÑÐ¾Ð¾ÑÐ²ÐµÑÑÑÐ²ÑÑÑÐµÐ¼Ñ ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½Ð¾Ð¼Ñ ÑÐµÐ»Ð¾Ð²ÐµÑÐµÑÐºÐ¾Ð¼Ñ Ð±ÐµÐ»ÐºÑ. ÐÐ° Ð¿Ð°Ð½ÐµÐ»Ð¸ ÐºÐ»ÐµÑÐ¾ÑÐ½ÑÑ Ð»Ð¸Ð½Ð¸Ð¹ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ° Ð¿ÑÐ¾Ð´ÐµÐ¼Ð¾Ð½ÑÑÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð¾ ÑÐ²ÑÐ·ÑÐ²Ð°Ð½Ð¸Ðµ Ñ ÑÐ°Ð·Ð»Ð¸ÑÐ½Ð¾Ð¹ ÑÑÑÐµÐºÑÐ¸Ð²Ð½Ð¾ÑÑÑÑ Ð¼ÐÐ¢ Ñ Ð½Ð°ÑÐ¸Ð²Ð½ÑÐ¼Ð¸ Ð°Ð½ÑÐ¸Ð³ÐµÐ½Ð°Ð¼Ð¸ VEGFR-1 Ð¸ Ð¡TLA-4 Ð¸ ÑÐ²ÑÐ·ÑÐ²Ð°Ð½Ð¸Ðµ Ð¼ÐÐ¢ Ñ Ð½Ð°ÑÐ¸Ð²Ð½ÑÐ¼ Ð°Ð½ÑÐ¸Ð³ÐµÐ½Ð¾Ð¼ Stabilin-1 Ð½Ð° Ð¿Ð¾Ð²ÐµÑÑÐ½Ð¾ÑÑÐ¸ Ð¼Ð°ÐºÑÐ¾ÑÐ°Ð³Ð¾Ð² ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°. ÐÐ»Ñ ÐºÐÐ¢ Ð½Ðµ Ð±ÑÐ»Ð¾ Ð²ÑÑÐ²Ð»ÐµÐ½Ð¾ ÑÐ²ÑÐ·ÑÐ²Ð°Ð½Ð¸Ñ Ñ ÑÐ¾Ð¾ÑÐ²ÐµÑÑÑÐ²ÑÑÑÐ¸Ð¼Ð¸ Ð°Ð½ÑÐ¸Ð³ÐµÐ½Ð°Ð¼Ð¸ Ð½Ð¸ Ð² Ð¾Ð´Ð½Ð¾Ð¹ Ð¸Ð· Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð½ÑÑ ÐºÐ»ÐµÑÐ¾ÑÐ½ÑÑ Ð»Ð¸Ð½Ð¸Ð¹. ÐÑÑÐ»ÐµÐ´ÑÐµÐ¼Ð¾Ðµ Ð¼ÐÐ¢ Ð¿ÑÐ¾ÑÐ¸Ð² ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ° VEGFR-1 Ð¾ÐºÐ°Ð·ÑÐ²Ð°ÐµÑ Ð°Ð½ÑÐ¸Ð¿ÑÐ¾Ð»Ð¸ÑÐµÑÐ°ÑÐ¸Ð²Ð½Ð¾Ðµ Ð²Ð¾Ð·Ð´ÐµÐ¹ÑÑÐ²Ð¸Ðµ Ð½Ð° ÑÑÐ´ Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²ÑÑ ÐºÐ»ÐµÑÐ¾ÑÐ½ÑÑ Ð»Ð¸Ð½Ð¸Ð¹, Ð½Ð¾ Ð½Ð° ÐºÐ»ÐµÑÐºÐ¸ Ð½Ð¾ÑÐ¼Ð°Ð»ÑÐ½Ð¾Ð¹ Ð¼Ð¾ÑÑÐ¾Ð»Ð¾Ð³Ð¸Ð¸ Ð¾Ð½Ð¾ Ð½Ðµ Ð¾ÐºÐ°Ð·ÑÐ²Ð°ÐµÑ Ð²ÑÑÐ°Ð¶ÐµÐ½Ð½Ð¾Ð³Ð¾ ÑÐ¸ÑÐ¾ÑÐ¾ÐºÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ ÑÑÑÐµÐºÑÐ°. Ð¥Ð°ÑÐ°ÐºÑÐµÑÐ¸Ð·ÑÐµÐ¼ÑÐµ Ð¼ÐÐ¢ Ð¿ÑÐ¾ÑÐ¸Ð² Ð¡TLA-4 Ð¸Ð»Ð¸ Stabilin-1, Ð° ÑÐ°ÐºÐ¶Ðµ ÐºÐÐ¢ Ð¿ÑÐ¾ÑÐ¸Ð² Ð²ÑÐµÑ ÑÑÐµÑ ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ¾Ð² Ð½Ðµ Ð¿ÑÐ¾Ð´ÐµÐ¼Ð¾Ð½ÑÑÑÐ¸ÑÐ¾Ð²Ð°Ð»Ð¸ Ð·Ð½Ð°ÑÐ¸Ð¼Ð¾Ð³Ð¾ Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ ÑÐ¾ÑÑÐ° Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²ÑÑ ÐºÐ»ÐµÑÐ¾Ðº ÑÐµÐ»Ð¾Ð²ÐµÐºÐ°. Ð¢Ð°ÐºÐ¶Ðµ Ð¿Ð¾Ð»ÑÑÐµÐ½Ð° ÐºÐ»ÐµÑÐ¾ÑÐ½Ð°Ñ Ð»Ð¸Ð½Ð¸Ñ ÑÐµÐ»Ð¾Ð²ÐµÐºÐ° ÐÐÐ-293Ð¢, ÑÑÐ°Ð±Ð¸Ð»ÑÐ½Ð¾ ÑÐºÑÐ¿ÑÐµÑÑÐ¸ÑÑÑÑÐ°Ñ Ð±Ð¸ÐÐ¢, Ð½ÐµÑÑÑÐµÐµ Ð´Ð¾Ð¼ÐµÐ½Ñ ÑÐ²ÑÐ·ÑÐ²Ð°Ð½Ð¸Ñ ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ¾Ð² VEGFR-1 Ð¸ Stabilin-1.
description: The given work is devoted to the characterisation of monoclonal (mAbs) and recombinant (control) antibodies (cAbs) to VEGFR-1, CTLA-4 and Stabilin-1 receptors presented on tumour stroma cells and to obtaining a cell line producing a bispecific antibody (bispAb). The affinity of the antibodies was tested by ELISA, and the ability to bind to native antigen by flow cytometry. The proliferative activity of cells in the presence of antibodies was evaluated on the xCellLigence system. As a result, it was shown that all tested mAbs and cAbs to VEGFR-1 receptor have high affinity to the corresponding recombinant human protein. A panel of human cell lines demonstrated binding of mAbs to native VEGFR-1 and CTLA-4 antigens and binding of mAbs to native Stabilin-1 antigen on the surface of human macrophages with varying efficiencies. For cAbs, no binding to the respective antigens was detected in any of the cell lines studied. The studied mAbs against the VEGFR-1 receptor has an antiproliferative effect on a number of tumour cell lines, but it has no pronounced cytotoxic effect on cells of normal morphology. Characterized mAbs against CTLA-4 or Stabilin-1, as well as cAbs against all three receptors, did not demonstrate significant growth inhibition of human tumour cells. A human cell line HEK-293T stably expressing bispAb carrying the binding domains of VEGFR-1 and Stabilin-1 receptors was also obtained.